Technical Analysis for ATNF - 180 Life Sciences Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical ATNF trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Death Cross | Bearish | -7.47% | |
| Bullish Engulfing | Bullish | -7.47% | |
| Bollinger Band Squeeze | Range Contraction | -7.47% | |
| BB Squeeze Started | Range Contraction | -7.47% | |
| Outside Day | Range Expansion | -7.47% | |
| 180 Bearish Setup | Bearish Swing Setup | -3.63% | |
| Narrow Range Bar | Range Contraction | -3.63% | |
| NR7 | Range Contraction | -3.63% | |
| Pocket Pivot | Bullish Swing Setup | -8.74% | |
| Doji - Bullish? | Reversal | -8.74% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 27 minutes ago |
| Fell Below Lower Bollinger Band | about 4 hours ago |
| Fell Below Previous Day's Low | about 4 hours ago |
| Down 5% | about 5 hours ago |
| 1.5x Volume Pace | about 5 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/04/2019
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials.
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Clinical Medicine Immunology Pain Disease Inflammation Inflammatory Disease Inflammatory Diseases Fibrosis Cytokines Tumor Necrosis Factor Animal Physiology Stanford University Human Physiology
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Clinical Medicine Immunology Pain Disease Inflammation Inflammatory Disease Inflammatory Diseases Fibrosis Cytokines Tumor Necrosis Factor Animal Physiology Stanford University Human Physiology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.04 |
| 52 Week Low | 1.9 |
| Average Volume | 797,689 |
| 200-Day Moving Average | 6.78 |
| 50-Day Moving Average | 6.75 |
| 20-Day Moving Average | 6.00 |
| 10-Day Moving Average | 5.97 |
| Average True Range | 0.58 |
| ADX | 11.47 |
| +DI | 16.89 |
| -DI | 19.01 |
| Chandelier Exit (Long, 3 ATRs) | 5.17 |
| Chandelier Exit (Short, 3 ATRs) | 6.80 |
| Upper Bollinger Bands | 6.66 |
| Lower Bollinger Band | 5.34 |
| Percent B (%b) | 0.33 |
| BandWidth | 21.93 |
| MACD Line | -0.26 |
| MACD Signal Line | -0.29 |
| MACD Histogram | 0.0377 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.34 | ||||
| Resistance 3 (R3) | 6.30 | 6.07 | 6.25 | ||
| Resistance 2 (R2) | 6.07 | 5.92 | 6.09 | 6.22 | |
| Resistance 1 (R1) | 5.92 | 5.83 | 5.99 | 5.96 | 6.18 |
| Pivot Point | 5.68 | 5.68 | 5.72 | 5.70 | 5.68 |
| Support 1 (S1) | 5.53 | 5.54 | 5.61 | 5.58 | 5.36 |
| Support 2 (S2) | 5.30 | 5.45 | 5.32 | 5.32 | |
| Support 3 (S3) | 5.15 | 5.30 | 5.29 | ||
| Support 4 (S4) | 5.20 |
